Related Experiment Video

Updated: Aug 30, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.4K

Therapeutic effect of monophosphoryl lipid A administration on Paracoccidioides brasiliensis-infected mice

Taise Natali Landgraf1, Fabrício Freitas Fernandes2, Gabriela Peron3

  • 1Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Medical Mycology
|September 18, 2016
PubMed

Insights

Monophoryl lipid A (MPLA) shows promise as a safe adjuvant for treating paracoccidioidomycosis (PCM). This immunotherapy reduces fungal load and boosts protective immune responses, offering a potential new avenue for PCM treatment.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Pharmacology

Background:

  • Paracoccidioidomycosis (PCM) lacks effective antifungals with low toxicity and short-term therapy.
  • Previous research indicated Complete Freund's Adjuvant (CFA) as therapeutic for experimental PCM.
  • CFA's toxicity necessitates exploring safer adjuvant alternatives.

Purpose of the Study:

  • To evaluate clinically approved or preclinical adjuvants for immunotherapy in experimental mouse PCM.
  • To identify adjuvants that can mitigate the toxicity associated with CFA.
  • To assess the therapeutic potential of novel adjuvants in improving PCM intervention.

Main Methods:

  • Experimental mouse model of paracoccidioidomycosis (PCM).
  • Administration of various adjuvants approved for clinical use or in preclinical development.
  • Assessment of fungal burden reduction.
  • Measurement of key immune mediator concentrations, including IFN-γ and TNF-α.

Main Results:

  • Monophoryl lipid A (MPLA) was the only adjuvant demonstrating a beneficial effect.
  • MPLA significantly reduced fungal burden in experimental PCM.
  • MPLA treatment led to increased concentrations of immunoprotective cytokines IFN-γ and TNF-α.

Conclusions:

  • MPLA exhibits therapeutic potential in experimental PCM.
  • MPLA may serve as a safer and effective adjuvant for immunotherapy in PCM.
  • Further investigation into MPLA-based immunotherapy for PCM is warranted.
Keywords:
Paracoccidioides brasiliensisadjuvantsimmunotherapymonophosphoryl lipid Aparacoccidioidomycosis

More Related Videos

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.4K
Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis06:57

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

3.1K

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...